BR112014003420A2 - hemifumarato de tenofovir alafenamida - Google Patents

hemifumarato de tenofovir alafenamida

Info

Publication number
BR112014003420A2
BR112014003420A2 BR112014003420A BR112014003420A BR112014003420A2 BR 112014003420 A2 BR112014003420 A2 BR 112014003420A2 BR 112014003420 A BR112014003420 A BR 112014003420A BR 112014003420 A BR112014003420 A BR 112014003420A BR 112014003420 A2 BR112014003420 A2 BR 112014003420A2
Authority
BR
Brazil
Prior art keywords
tenofovir alafenamide
alafenamide hemifumarate
hemifumarate
tenofovir
phenoxyphosphinyl
Prior art date
Application number
BR112014003420A
Other languages
English (en)
Other versions
BR112014003420B1 (pt
Inventor
Shi Bing
Liu Dazhan
Wang Fang
Hung Chiu Yu Richard
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014003420(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112014003420A2 publication Critical patent/BR112014003420A2/pt
Publication of BR112014003420B1 publication Critical patent/BR112014003420B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "hemifumarato de tenofovir alafenamida". a presente invenção refere-se a uma forma de hemifumarato de 9-[(r)-2-[[(s)-[[(s)-1-(isopropoxicarbonil)etil]amino]fenoxifosfinil]-metóxi]propil]adenina (tenofovir alafenamida) e à terapia antiviral usando hemifumarato de tenofovir alafenamida (por exemplo, terapias anti-hiv e anti-hbv). 20507101v1
BR112014003420-6A 2011-08-16 2012-08-15 Hemifumarato de tenofovir alafenamida. composição, seus métodos de preparação e uso BR112014003420B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16
US61/524,224 2011-08-16
PCT/US2012/050920 WO2013025788A1 (en) 2011-08-16 2012-08-15 Tenofovir alafenamide hemifumarate

Publications (2)

Publication Number Publication Date
BR112014003420A2 true BR112014003420A2 (pt) 2017-03-01
BR112014003420B1 BR112014003420B1 (pt) 2021-07-20

Family

ID=46785793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003420-6A BR112014003420B1 (pt) 2011-08-16 2012-08-15 Hemifumarato de tenofovir alafenamida. composição, seus métodos de preparação e uso

Country Status (41)

Country Link
US (2) US8754065B2 (pt)
EP (3) EP3831832A1 (pt)
JP (5) JP5651275B2 (pt)
KR (1) KR101612642B1 (pt)
CN (2) CN103732594A (pt)
AP (1) AP3639A (pt)
AR (1) AR087546A1 (pt)
AU (1) AU2012296622C1 (pt)
BR (1) BR112014003420B1 (pt)
CA (1) CA2845553C (pt)
CL (1) CL2014000370A1 (pt)
CO (1) CO6880063A2 (pt)
CR (1) CR20140072A (pt)
CY (1) CY1118385T1 (pt)
DK (1) DK2744810T4 (pt)
EA (1) EA027768B1 (pt)
EC (1) ECSP14013206A (pt)
ES (1) ES2608871T5 (pt)
FI (1) FI2744810T4 (pt)
HK (1) HK1199026A1 (pt)
HR (1) HRP20161696T4 (pt)
HU (1) HUE031253T2 (pt)
IL (2) IL230949A (pt)
IN (1) IN2014DN01012A (pt)
LT (1) LT2744810T (pt)
MA (1) MA35350B1 (pt)
MD (1) MD4508C1 (pt)
ME (1) ME02612B (pt)
MX (1) MX336627B (pt)
PE (1) PE20141328A1 (pt)
PL (1) PL2744810T5 (pt)
PT (1) PT2744810T (pt)
RS (1) RS55353B2 (pt)
SG (1) SG2014011548A (pt)
SI (1) SI2744810T2 (pt)
SM (1) SMT201600476B (pt)
TW (1) TWI516499B (pt)
UA (1) UA115311C2 (pt)
UY (1) UY34262A (pt)
WO (1) WO2013025788A1 (pt)
ZA (1) ZA201400582B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US8664386B2 (en) 2011-10-07 2014-03-04 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
EP3240793A1 (en) * 2015-01-03 2017-11-08 Mylan Laboratories Ltd. Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
AU2016277859B2 (en) * 2015-06-17 2019-08-01 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
SI4070787T1 (sl) 2015-06-30 2023-07-31 Gilead Sciences, Inc. Farmacevtske formulacije
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TWI639598B (zh) 2015-08-10 2018-11-01 美商默沙東藥廠 抗病毒β－胺基酸酯磷酸二醯胺化合物
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
TWI737647B (zh) 2015-11-09 2021-09-01 美商基利科學股份有限公司 用於治療人類免疫缺乏病毒之治療組合物
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
CN109476689B (zh) 2016-06-05 2021-09-03 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
CA3021227C (en) 2016-08-19 2020-11-03 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2018039157A1 (en) 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
CN113072583A (zh) * 2016-11-28 2021-07-06 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
CA3046029A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
BR112019013017A2 (pt) 2016-12-22 2020-01-14 Idenix Pharmaceuticals Llc compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
WO2018113652A1 (zh) 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
AR110768A1 (es) * 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019130354A1 (en) 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
CA3090280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
EP3808752A4 (en) 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
JP2021530523A (ja) 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
CN112996517A (zh) 2018-09-19 2021-06-18 吉利德科学公司 预防hiv的整合酶抑制剂
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
WO2021165995A1 (en) * 2020-02-20 2021-08-26 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
AU2021377614A1 (en) 2020-11-11 2023-06-22 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
JP4033494B2 (ja) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
ES2198003T3 (es) 1996-07-26 2004-01-16 Gilead Sciences, Inc. Analogos de nucleotidos.
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
AU756793B2 (en) 1997-07-25 2003-01-23 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
JP4651264B2 (ja) * 2000-07-21 2011-03-16 ギリアード サイエンシーズ， インコーポレイテッド ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
TWI275392B (en) 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
EP3696171A1 (en) 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2532502T3 (es) 2006-07-12 2015-03-27 Mylan Laboratories Limited Proceso para la preparación de tenofovir
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
KR101923103B1 (ko) 2010-11-19 2018-11-28 길리애드 사이언시즈, 인코포레이티드 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US8664386B2 (en) 2011-10-07 2014-03-04 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
MD20140091A2 (ro) † 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale

Also Published As

Publication number Publication date
AR087546A1 (es) 2014-04-03
AU2012296622B2 (en) 2014-09-11
CL2014000370A1 (es) 2014-09-05
CN103732594A (zh) 2014-04-16
JP2014528924A (ja) 2014-10-30
TWI516499B (zh) 2016-01-11
EP3831832A1 (en) 2021-06-09
EP2744810B1 (en) 2016-10-05
FI2744810T4 (fi) 2023-11-22
MD4508C1 (ro) 2018-03-31
AU2012296622A1 (en) 2013-05-09
EP3070088A1 (en) 2016-09-21
IN2014DN01012A (pt) 2015-05-15
ES2608871T3 (es) 2017-04-17
DK2744810T4 (da) 2023-11-20
JP5651275B2 (ja) 2015-01-07
JP2020040972A (ja) 2020-03-19
EA027768B1 (ru) 2017-08-31
HUE031253T2 (en) 2017-07-28
US20130065856A1 (en) 2013-03-14
WO2013025788A1 (en) 2013-02-21
PE20141328A1 (es) 2014-10-04
EP2744810B2 (en) 2023-09-13
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
CO6880063A2 (es) 2014-02-28
PL2744810T3 (pl) 2017-04-28
SG2014011548A (en) 2014-09-26
DK2744810T3 (en) 2016-12-05
PT2744810T (pt) 2016-11-04
HRP20161696T1 (hr) 2017-02-24
PL2744810T5 (pl) 2024-02-05
IL230949A0 (en) 2014-03-31
JP5956537B2 (ja) 2016-07-27
RS55353B2 (sr) 2023-11-30
IL230949A (en) 2015-09-24
LT2744810T (lt) 2016-11-25
NZ620421A (en) 2015-05-29
AU2012296622C1 (en) 2017-02-16
MX336627B (es) 2016-01-26
KR20140054068A (ko) 2014-05-08
ECSP14013206A (es) 2014-03-31
MA35350B1 (fr) 2014-08-01
US8754065B2 (en) 2014-06-17
MD20140011A2 (en) 2014-05-31
MD4508B1 (ro) 2017-08-31
AP3639A (en) 2016-03-13
ME02612B (me) 2017-06-20
ZA201400582B (en) 2017-11-29
CA2845553C (en) 2019-05-28
IL240649A0 (en) 2015-09-24
JP2018065870A (ja) 2018-04-26
RS55353B1 (sr) 2017-03-31
CN110343135A (zh) 2019-10-18
EA201490208A1 (ru) 2014-06-30
SI2744810T2 (sl) 2023-11-30
HRP20161696T4 (hr) 2023-10-13
UA115311C2 (uk) 2017-10-25
JP2015038149A (ja) 2015-02-26
KR101612642B1 (ko) 2016-04-14
JP6280162B2 (ja) 2018-02-14
US20140187773A1 (en) 2014-07-03
CR20140072A (es) 2014-06-19
TW201321396A (zh) 2013-06-01
ES2608871T5 (es) 2024-04-04
HK1199026A1 (en) 2015-06-19
CY1118385T1 (el) 2017-06-28
US9296769B2 (en) 2016-03-29
UY34262A (es) 2013-04-05
CA2845553A1 (en) 2013-02-21
SMT201600476B (it) 2017-03-08
JP2016169228A (ja) 2016-09-23
EP2744810A1 (en) 2014-06-25
BR112014003420B1 (pt) 2021-07-20
AP2014007437A0 (en) 2014-02-28

Similar Documents

Publication Publication Date Title
BR112014003420A2 (pt) hemifumarato de tenofovir alafenamida
EA201491287A1 (ru) Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
EP2731433A4 (en) 5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
EP2697242A4 (en) 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
BR112015026325A2 (pt) dosagem oral de compostos glp-1
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
IN2014CN00989A (pt)
EP2696679A4 (en) 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
EA201490233A8 (ru) Стабильные лекарственные формы артеролана и пиперахина
EP2726102A4 (en) PROCESSES AND COMPOSITIONS OF PROTEIN ANTIGENES FOR DIAGNOSIS AND TREATMENT OF HERPES SIMPLEX VIRUS TYPES 1 AND 2
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
BR112014009217A2 (pt) antibacterianos à base de fenicol
TH162157A (th) เทโนโฟเวียร์ อะลาเฟนามายด์ เฮมิฟูมาเรต(Tenofovir alafenamide hemifumarate)
BR112013025934A2 (pt) tratamento de infecção pelo vírus da hepatite c com alisporivir
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2012, OBSERVADAS AS CONDICOES LEGAIS.